Melanoma: baseline predictors of dabrafenib + trametinib efficacy

Access to the full content of this site is available only to registered healthcare professionals. Register to read more
Takeaway
  • Pooled analysis using the largest data set available for BRAF and MEK inhibitor combination treatment in melanoma identified patient and clinical factors that can help predict outcomes with dabrafenib (Tafinlar) plus trametinib (Mekinist) treatment.
Why this matters
  • The findings can help ...